InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1 |
XIQVNETUBQGFHX-JOCHJYFZSA-N |
C1(CCCCC1)[C@](C2=CC=CC=C2)(C(OCC#CCN(CC)CC)=O)O |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
muscarinic antagonist
A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
calcium channel blocker
One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
|
|
muscarinic antagonist
A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
local anaesthetic
Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
|
|
View more via ChEBI Ontology
4-(diethylamino)but-2-yn-1-yl (2S)-cyclohexyl(hydroxy)phenylacetate
|
esoxibutinina
|
WHO MedNet
|
esoxybutynin
|
WHO MedNet
|
ésoxybutynine
|
WHO MedNet
|
esoxybutyninum
|
WHO MedNet
|
(+)-oxybutynin
|
ChEBI
|
(S)-(+)-oxybutynin
|
ChEBI
|
(S)-oxybutynin
|
ChEBI
|
119618-22-3
|
CAS Registry Number
|
ChemIDplus
|
10987980
|
PubMed citation
|
Europe PMC
|
12001823
|
PubMed citation
|
Europe PMC
|
12431028
|
PubMed citation
|
Europe PMC
|
24036364
|
PubMed citation
|
Europe PMC
|
25215879
|
PubMed citation
|
Europe PMC
|
26852022
|
PubMed citation
|
Europe PMC
|
|